» Articles » PMID: 2482772

Etiology and Disease Process of Benign Prostatic Hyperplasia

Overview
Journal Prostate Suppl
Specialty Urology
Date 1989 Jan 1
PMID 2482772
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

The natural history of benign prostatic hyperplasia (BPH) involves two phases. The first, or pathological phase of BPH, involves two stages, termed microscopic and macroscopic BPH, neither of which produces symptomatic clinical dysuria. Nearly all men throughout the world will eventually develop microscopic BPH if they live long enough. In only about one-half of the men with microscopic BPH, however, will microscopic BPH grow to produce a macroscopic enlargement of the gland (i.e., macroscopic BPH), suggesting that additional factors are required for the progression of microscopic to macroscopic BPH. Several theories have been proposed to explain the etiology of the pathological phase of BPH. The major theories include the hypotheses that pathological BPH is due to 1) a shift in prostatic androgen metabolism that occurs with aging, which leads to an abnormal accumulation of dihydrotestosterone, thus producing the enlarged prostate (i.e., DHT hypothesis), 2) a change in the prostatic stromal-epithelial interact that occurs with aging, which leads to an inductive effect on prostatic growth (i.e., embryonic reawakening theory), or 3) an increase in the total prostatic stem cell number and/or an increase in the clonal expanding of the stem cells into amplifying and transit cells that occurs with aging (i.e., stem cell theory). The second, or clinical phase of BPH, involves the progression of pathologic BPH to clinical BPH in which the patient develops symptomatic dysuria. Only about one-half the men with macroscopic BPH progress to clinical BPH. Although the macroscopic enlargement of the prostate is a necessary condition for the development of clinical BPH, this enlargement is usually not sufficient by itself for the progression of pathologic BPH to clinical BPH. The etiology of the progression of pathological BPH to clinical BPH requires additional factors (e.g., prostatitis, vascular infarct, tensile strength of the glandular capsule, etc.). A successful treatment for clinical BPH, therefore, does not necessarily require either the prevention or elimination of all degrees of pathologic BPH. Instead, what is needed is a therapy to prevent or reverse the progression of pathologic BPH to the clinical disease.

Citing Articles

The role of RhoA-ROCK signaling in benign prostatic hyperplasia: a review.

Shan S, Su M Hum Cell. 2025; 38(2):48.

PMID: 39891836 DOI: 10.1007/s13577-025-01179-x.


Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating Androgen Levels, Cell Proliferation, and Apoptosis.

Kumbukgahadeniya P, Baek E, Hong E, Song J, Kwak Y, Jang M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598426 PMC: 11597678. DOI: 10.3390/ph17111516.


The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy.

Xu G, Dai G, Huang Z, Guan Q, Du C, Xu X Res Rep Urol. 2024; 16:205-214.

PMID: 39345801 PMC: 11430843. DOI: 10.2147/RRU.S477396.


CCR2 monocytes/macrophages drive steroid hormone imbalance-related prostatic fibrosis.

Popovics P, Silver S, Uchtmann K, Arendt L, Vezina C, Ricke W Sci Rep. 2024; 14(1):15736.

PMID: 38977751 PMC: 11231243. DOI: 10.1038/s41598-024-65574-4.


Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells.

Kirk J, Wang J, Long M, Rosario S, Tracz A, Ji Y Cell Stem Cell. 2024; 31(8):1203-1221.e7.

PMID: 38878775 PMC: 11297676. DOI: 10.1016/j.stem.2024.05.008.